Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin in Older Patients With Relapsed/Refractory AML
NCT00895934Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2009
- Primary completion
- Jul 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started May 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00895934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895934.